OT-82 is under clinical development by OncoTartis and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OT-82’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OT-82 overview

OT-82 is under development for the treatment of adult and pediatric hematological malignancy like ALL, Ewing sarcoma, melanoma, acute myeloblastic leukemia (AML), mixed lineage leukemia (MLL), acute lymphocytic leukemia, multiple myeloma, eryhthroleukemia, relapsed/refractory follicular lymphoma, Mantle cell lymphoma, marginal B cell lymphoma, primary mediastinal B cell lymphoma, diffuse large B cell lymphoma, peripheral T cell lymphomas and Hodgkin lymphoma. It is administered through oral route. The drug candidate is developed based on the targeting tissue (TARTIS) technology. It acts by targeting Nicotinamide phosphoribosyl transferase (NAMPT). It was under development for the treatment of lymphoplasmacytic lymphoma,

OncoTartis overview

OncoTartis is a biotechnology company that develops drugs to treat various types of cancers. The company offers lead candidate OT-82, an orally available nicotinamide phosphoribosyl transferase inhibitor (NAMPT), which is being developed for treating range of acute myeloid leukemia. It also develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers such as breast, prostate, ovarian, melanoma and hematological malignancies. OncoTartis’ utilizes Tartis, a proprietary integrated drug and target discovery platform for identification of small molecules and shRNAs compounds corresponding to specific genes. The company carries research and development activities in both chemical and biological screenings with cell phenotype-based readout systems. OncoTartis is headquartered in Buffalo, New York, the US.

For a complete picture of OT-82’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.